Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28723085 | 1.00 | ALOX5 (0.33) | ALOX5SMYD3DPP4 | |
| SCHEMBL14336109 | 1.00 | ALOX5 (0.33) | ALOX5SMYD3DPP4 | |
| SCHEMBL8227849 | 1.00 | ALOX5 (0.33) | ALOX5SMYD3DPP4 | |
| SCHEMBL13775302 | 1.00 | ALOX5 (0.33) | ALOX5SMYD3DPP4 | |
| SCHEMBL18987904 | 1.00 | ALOX5 (0.33) | ALOX5SMYD3DPP4 | |
| Hydrochloric Acid SCHEMBL18988009 | 0.97 | ALOX5 (0.32) | ALOX5SMYD3DPP4 | |
| Hydrochloric Acid SCHEMBL18988007 | 0.97 | ALOX5 (0.32) | ALOX5SMYD3DPP4 | |
| Hydrochloric Acid SCHEMBL4933747 | 0.97 | ALOX5 (0.32) | ALOX5SMYD3DPP4 | |
| Hydrochloric Acid SCHEMBL21222289 | 0.97 | ALOX5 (0.32) | ALOX5SMYD3DPP4 | |
| Hydrochloric Acid SCHEMBL4933740 | 0.97 | ALOX5 (0.32) | ALOX5SMYD3DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138990-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260078127-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INT (DE) | 2026-03-19 | — | — | US | disclosed |
| EP-4702026-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12398146-B2 | Heterobicyclic amides as inhibitors of CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-08-26 | — | — | US | disclosed |
| CN-119431323-A | Heterobicyclic amides as CD38 inhibitors | 贝林格尔·英格海姆国际有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20240368167-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-11-07 | — | — | US | disclosed |
| WO-2024226685-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| CN-114423753-B | Heterobicyclic amides as CD38 inhibitors | 里邦医疗公司 | 2024-09-17 | — | — | CN | disclosed |
| US-11987584-B2 | Heterobicyclic amides as inhibitors of CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-05-21 | — | — | US | disclosed |
| US-20230312586-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-05 | — | — | US | disclosed |
| US-20080058369-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors | GLAXO GROUP LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| US-20080058369-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors | GLAXO GROUP LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| WO-2008015416-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008015437-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008009735-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | WO | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| WO-2007036733-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| WO-2005058892-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138990-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | CD38, BCL9, BCL6B | ALOX5 2204/4885SMYD3 2766/4885DPP4 3226/4885 |
| US-20240368167-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, PARP12, ENTPD2 | ALOX5 2583/4885SMYD3 3464/4885DPP4 2005/4885 |
| US-12398146-B2 | Heterobicyclic amides as inhibitors of CD38 | CD38, PARP12, ENTPD2 | ALOX5 2583/4885SMYD3 3464/4885DPP4 2005/4885 |
| US-20230312586-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, PARP12, ENTPD2 | ALOX5 2583/4885SMYD3 3464/4885DPP4 2005/4885 |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | PDE4B, PDE3B, PDE4A | ALOX5 1828/4885SMYD3 1413/4885DPP4 45/4885 |
| US-20260078127-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, CD22, CD79B | ALOX5 3267/4885SMYD3 3059/4885DPP4 3660/4885 |
| US-20080058369-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors | PDE4A, PDE4B, PDE3B | ALOX5 897/4885SMYD3 389/4885DPP4 20/4885 |
| US-11987584-B2 | Heterobicyclic amides as inhibitors of CD38 | CD38, PARP12, ENTPD2 | ALOX5 2583/4885SMYD3 3464/4885DPP4 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.